Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.
Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Application for olezarsen, targeting severe hypertriglyceridemia and reduction of acute pancreatitis risk. The company ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsBrett Monia - Founder, ...
Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...
In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 ...
CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $229 million in its fourth quarter. On a per-share basis, the Carlsbad, ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results